PHGE: מכפיל P/S עתידי BiomX

The projected P/S metric exhibits volatility as BiomX Inc. prepares its methods for combating resistant bacteria for sale. The 7.10 mark characterizes this parameter, with a closed-loop therapy based on phage cocktails serving as the foundation. However, the clinical testing stage is increasing laboratory expenses, which temporarily neutralizes the company's operating leverage.

For BiomX Inc. (PHGE), which is restructuring its R&D portfolio to accelerate clinical trials, this indicator serves as a tool to verify market value relative to expected cash flows. By analyzing the forward price-to-sales ratio, an investor correlates current market capitalization with expected annual revenue, making it possible to distinguish fundamental asset undervaluation from systemic risks during the management's operational adaptation period.